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The bioaccessibility of arsenic and its speciation are two important factors in 17 
assessing human health risks exposure to contaminated soils. However, the effects of 18 
human gut microbiota on arsenic bioaccessibility and its speciation are not well 19 
characterized. In this study, an improved in vitro model was utilized to investigate the 20 
bioaccessibility of arsenic in the digestive tract and the role of human gut microbiota 21 
in the regulation of arsenic speciation. For all soils, arsenic bioaccessibility from the 22 
combined in vitro model showed that it was < 40% in the gastric, small intestinal and 23 
colon phases. This finding demonstrated that the common bioaccessibility approach 24 
assuming 100% bioaccessibility would overestimate the human health risks posed by 25 
contaminated soils. Further to this, the study showed that arsenic bioaccessibility was 26 
22% higher in the active colon phase than that in the sterile colon phase indicating 27 
that human colon microorganisms could induce arsenic release from the solid phase. 28 
Only inorganic arsenic was detected in the gastric and small intestinal phases, with 29 
arsenate [As(V)] being the dominant arsenic species (74%-87% of total arsenic). 30 
Arsenic speciation was significantly altered by the active colon microbiota, which 31 
resulted in the formation of methylated arsenic species, including monomethylarsonic 32 
acid [MMA(V)] and dimethylarsinic acid [DMA(V)] with low toxicity, and a highly 33 
toxic arsenic species monomethylarsonous acid [MMA(III)]. Additionally, a high 34 
level of monomethylmonothioarsonic acid [MMMTA(V)] (up to 17% of total arsenic 35 
in the extraction solution) with unknown toxicological properties was also detected in 36 
the active colon phase. The formation of various organic arsenic species 37 




arsenic into methylated arsenicals and methylated thioarsenicals. Such transformation 39 
should be considered when assessing the human health risks associated with oral 40 
exposure to soil. 41 
Keywords: soils, arsenic bioaccessibility, human gut microbiota, in vitro models, 42 
health risk assessment 43 
Main findings: The human colon microbes could actively metabolize soil inorganic 44 




1. Introduction 46 
Arsenic is a ubiquitous element in the environment presenting high toxicity and 47 
carcinogenicity (Zhu et al., 2014). Soils have been proven to be important sinks for arsenic, 48 
and the chemical fractionations of arsenic feature differential labile phases and 49 
bioavailability in soils. Generally, arsenic in soil is dominantly associated with iron (Fe) 50 
oxides, amorphous manganese (Mn) and aluminum (Al) that can pose detrimental health 51 
effects to humans (Niazi et al., 2011). An increasing body of evidence establishes a clear 52 
correlation between arsenic and human diseases, such as Blackfoot disease (Tseng, 2005), 53 
neonatal death (Milton et al., 2005) and even cancers (Lin et al., 2013; Zhou and Xi, 2018). 54 
Although inhalation of arsenic-containing particles contributes negligibly to arsenic exposure 55 
(Meacher et al., 2002), incidental oral ingestion of soil is, however, an important exposure 56 
route for arsenic, especially for children (Ljung et al., 2006). The reported human soil 57 
ingestion rates generally range between 37 and 207 mg d-1 for children (Davis and Mirick, 58 
2006). Considering the notable ingestion of soil, the human health risk associated with oral 59 
exposure to soil arsenic is becoming a public issue (Luo et al., 2012). 60 
Several human health risk assessments for heavy metals contaminated sites rely on the 61 
use of over conservative estimation based on the total concentration of the element 62 
considered (Liao et al., 2005; Wcis ł o et al., 2016). However, recent studies have 63 
demonstrated that the physiological and mineralogical properties of the soils influence 64 
element dissolution and gastrointestinal absorption (Frau and Ardau, 2004; Ruby et al., 1999; 65 
Stýblo et al., 2002). Thus, to overcome this risk overestimation, several studies developed in 66 
vivo models, using rodents, rabbits and swine, to quantify element bioavailability, especially 67 
for arsenic (Juhasz et al., 2007; Ng et al., 1998; Rodriguez et al., 1999; Li et al., 2019). 68 




issues (Basta et al., 2007). Thus, simple, fast and inexpensive in vitro models such as the 70 
physiologically based extraction test (PBET), In vitro gastrointestinal method (IVG), simple 71 
bioaccessibility extraction test (SBET) and unified BARGE method (UBM) models have 72 
been developed to measure the fraction of arsenic that is released from the soil for intestinal 73 
tract absorption (the bioaccessible fraction) (Ruby et al., 1996; Sarkar et al., 2007). 74 
Furthermore, these in vitro models have been validated for predicting arsenic relative 75 
bioavailability by establishing the in vivo-in vitro correlations (IVIVC) (Juhasz et al., 2009; 76 
Li et al., 2015). Given that bioaccessibility is one of the principal factors limiting arsenic 77 
assimilation, such insight is invaluable in the assessment of exposure risk. Assessing the 78 
health risks from ingesting arsenic-contaminated soil requires data on the arsenic ingestion 79 
rate, arsenic bioaccessibility in the gastrointestinal tract as well as the speciation of arsenic 80 
following gastrointestinal digestion of the soil, as its speciation largely determines its 81 
toxicity (Zhu et al., 2014). Although inorganic arsenic may be the major species in soil, 82 
arsenic speciation in the digestive tract is not well characterized (Alava et al., 2012). 83 
Furthermore, the colon, as one of the digestive organs, represents a highly reducing 84 
environment and provides a vast (up to 1014 bacterial cells) and diverse (above 1,000 85 
speciation) microbial community (Eckburg et al., 2010), which could influence arsenic 86 
bioaccessibility and speciation (Van de Wiele et al., 2010). However, most in vitro models 87 
only consider the digestive process that takes place in the stomach and small intestine 88 
(Oomen et al., 2002; Rodriguez et al., 1999; Ruby et al., 1996; Xia et al., 2016). Indeed, 89 
many compounds including arsenic could be transported across the epithelium in the colon, 90 
and health modulation by the human gut microbial community should not be underestimated 91 




colon from these in vitro models may be a shortcoming, as the colon represents a contrasting 93 
environment to the stomach and small intestine. 94 
A dynamic human gastrointestinal simulator known as the simulator of the human 95 
intestinal microbial ecosystem(SHIME) has been used to investigate the measurement of 96 
contaminants bioaccessibility by mimicking the physiological parameters of the human 97 
gastrointestinal tract (Ruby et al., 1993; Chi et al., 2018). Unlike other in vitro models, the 98 
SHIME model is seeded with microbial community cultures obtained from the human feces. 99 
Results obtained with the SHIME model have proven that the human colon microbiota can 100 
transform inorganic arsenic into organic arsenicals (Van de Wiele et al., 2010). To further 101 
explore arsenic transformation in all regions of the digestive tract, other in vitro models such 102 
as UBM, IVG, and PBET, were combined with SHIME to study arsenic bioaccessibility and 103 
speciation changes during passage through the gastrointestinal tract (Sun et al., 2012; Yin et 104 
al., 2015; Yin et al., 2016). Yin et al. (2015) found that a large amount of toxic arsenite 105 
[As(III)] was observed as a result of human gut microbial reduction by using a combined 106 
PBET-SHIME model, and various organic arsenic species, such as monomethylarsonic acid 107 
[MMA(V)], dimethylarsinic acid [DMA(V)] and monomethylmonothioarsonic acid 108 
[MMMTA(V)], were also observed in the active human colon stage. Furthermore, arsenic 109 
bioaccessibility varied in the colon phase among these methods (Yin et al., 2016). Sun et al. 110 
(2012) also found highly toxic monomethylarsonous acid [MMA(III)] in colon digests of 111 
arsenic-contaminated rice, resulting in a higher human health risk. These findings indicated 112 
that various arsenic transformations have occurred in the digestive tract, especially with the 113 
involvement of human gut microorganisms, which resulted in the complexity of human 114 
health risk assessment. However, studies of the effects of human gut microbiota on arsenic 115 




model, UBM-SHIME, was employed to evaluate (1) arsenic bioaccessibility and its 117 
relationship with arsenic fractionation in soils and (2) arsenic metabolism in soils by human 118 
gut microbiota. This study provides new insight into health risk assessments related to oral 119 




2. Materials and Methods 121 
2.1 Chemicals 122 
Ultrapure 18 mΩ water (DDI; Millipore, Bedford, MA, USA) was used to prepare the 123 
stock standard solutions and chromatographic mobile phase. Sodium arsenate 124 
(Na2HAsO4·12H2O) and sodium arsenite (NaAsO2) were purchased from BAL (Beijing, 125 
China), MMA(V) and DMA(V) were purchased from AccuStandard Inc (New Haven, CT), 126 
MMA(III) was purchased from Sigma Chemicals (Belgium), and MMMTA(V) was 127 
synthesized using a mixture of MMA(V) and an H2S solution (Sergio et al., 2014). Detailed 128 
information about the method used to synthesize MMMTA(V) is provided in Supporting 129 
Information. Chromatographic confirmation of the MMMTA(V) is shown in Figure S1. 130 
2.2 Soil collection and characterization 131 
Surface soil samples (0-20 cm) were collected from different types of sites, including 132 
mining land, chemical land, and battery plants. All collected soil samples were placed in 133 
nylon woven bags and transported back to the laboratory. Samples were then freeze-dried, 134 
crushed and sieved to 250 μm for in vitro gastrointestinal incubation. This reflects the size of 135 
particles that most likely stick to the hands and thereby provide a route of exposure to 136 
humans (Zagury, 2007). The dissolved organic carbon (DOC) fraction of the soil samples 137 
was extracted with ultrapure water (Yu et al., 2012), and a total organic carbon analyzer 138 
(TOC-L CPH, Shimadzu, Japan) was utilized for DOC measurement. The soils were 139 
digested using an HNO3 and HClO4 method for arsenic and other metals analysis (Lee et al., 140 
2006). Then, the concentrations of Fe and Mn were quantified by inductively coupled 141 
plasma-optical emission spectroscopy (ICP-OES, Optima 7000DV, PerkinElmer, USA) and 142 
inductively coupled plasma-mass spectrometry (ICP-MS, 7500a, Agilent Technologies, USA) 143 




soils were presented in Table 1. Arsenic speciation in soils was extracted by using a 300 mM 145 
phosphate solution of pH 6.0 at 40 oC (Alam et al., 2001), and HPLC-ICP-MS was utilized 146 
for arsenic speciation analysis. In the digestion process, blank and standard reference 147 
materials (GSS-1 and GSS-3, National Institute of Metrology, China) were employed to 148 
ensure the accuracy and recovery rates of arsenic (90.2%-118.9%). 149 
2.3 Sequential extraction of soil arsenic from soil 150 
Two sequential extraction procedures (SEPs), including the Tessier and Wenzel SEPs, 151 
were compared for arsenic fractionation in soils. Tessier SEP is a classical sequential 152 
extraction method for the partitioning of heavy metals into the exchangeable fraction (F1), 153 
the fraction bound to carbonates (F2), the fraction bound to Fe and Mn oxides (F3), the 154 
fraction bound to organic matter (F4) and the residual fraction (F5) (Tessier et al., 1979). 155 
The Wenzel SEP is an improved sequential extraction procedure specially developed for 156 
arsenic fractionation. With this procedure, the arsenic in soil is divided into the 157 
nonspecifically sorbed fraction (NS1), the specifically sorbed fraction (SS2), the amorphous 158 
and poorly crystalline hydrous oxides of Fe and Al fraction (AF3), the well-crystallized 159 
hydrous oxides of Fe and Al fraction (CF4) and the residual phases (RS5) (Wenzel et al., 160 
2001). The extracted supernatant was centrifuged and filtered through 0.22 μm filters for 161 
further analysis using ICP-MS (Agilent 7500a, USA). 162 
2.4 Production and characterization of colon microbiota for SHIME 163 
The colon microbial community utilized in this experiment was cultured and maintained 164 
in an improved SHIME model (Chi et al., 2018). The SHIME consisted of five 165 
double-jacketed vessels maintained at a temperature of 37 oC, which simulated the stomach, 166 
small intestine, and the ascending, transverse and descending colon, respectively. The colon 167 




descending colon at 5.6-5.9, 6.1-6.4 and 6.6-6.9, respectively. The SHIME reactors were 169 
continuously stirred and kept under anaerobic conditions by regularly flushing with nitrogen. 170 
After three weeks of adaptation, stable microbial communities were obtained from the 171 
descending colon compartments for further study. The total DNA extraction was conducted 172 
according to the manufacturer’s instructions for the FastDNA® Spin Kit for Soil (MP 173 
Biomedicals Inc, Santa Ana, USA). The general bacterial primers 338F-GC and 518R were 174 
used in PCR amplification (Figure S4). 175 
2.5 Arsenic bioaccessible assessment 176 
The in vitro approach was adapted from a UBM-SHIME method (Wragg et al., 2011; 177 
Chi et al., 2018). For the stomach phase: 0.36 g of soil was accurately added into a 100 mL 178 
brown serum bottle, and 5.4 mL of simulated saliva was added via a pipette and then 179 
manually shaken to thoroughly mix the soil and simulated fluids. Subsequently, simulated 180 
gastric fluid (8.1 mL) was added to each bottle. The solution pH was adjusted to 2.0 using 181 
HCl (1.0 M), high purity nitrogen gas was flushed into the bottles, which were then capped 182 
with a rubber stopper to ensure an anaerobic environment. Then, bottles were shaken (100 183 
rpm) at 37 oC for 1 h. In the small intestine phase, after 1 h of incubation, 16.2 mL of 184 
simulated duodenal fluid and 5.4 mL of simulated bile fluid were added into each bottle, and 185 
the pH was adjusted to 6.0 with NaOH (1.0 M) and flushed with nitrogen gas to ensure an 186 
anaerobic environment. These bottles were returned to the shaker for an additional 4 h. In the 187 
colon phase, 35.1 ml of colon SHIME solution from the descending compartment of the 188 
dynamic SHIME system was added to the bottles. Then, the bottles were capped with a 189 
rubber stopper, flushed with nitrogen gas for 30 min to replace the headspace and assure 190 
anaerobic conditions, placed in a shaker and incubated at 37 oC for an additional 48 h. A 191 




speciation modulation. Destructive sampling was carried out. The experiment was conducted 193 
in quadruplicate. To avoid contamination, all glassware, storage bottles, and centrifuge tubes 194 
were kept in 10% nitric acid for at least 24 h, rinsed three times with ultrapure water and 195 
dried before use. 196 
2.6 Chemical analysis 197 
To preserve the speciation of arsenic in the digestive phases, all samples from the 198 
stomach, small intestine and colon phases were immediately flash-frozen with liquid 199 
nitrogen and subsequently stored at -80 oC. The supernatants were centrifuged at 10,000 g for 200 
10 min and then passed through a 0.22 μm filter before analysis. The arsenic speciation was 201 
determined by high-performance liquid chromatography coupled with inductively coupled 202 
plasma-mass spectrometry (HPLC-ICP-MS). A Hamilton PRP-X100 column (250×4.6 mm, 203 
10 μm) (Yan et al., 2017) and a Phoenix C18 column (250×4.6 mm, 10 μm) (Yan et al., 2015) 204 
were used. The chromatographic condition details are provided in Table S1. Arsenic 205 
speciation in the digestive tract solution was identified by comparing their retention time to 206 
those of standards [As(III), As(V), MMA(III), MMA(V), DMA(V) and MMMTA(V)] and 207 
quantified by external calibration curves of DMA(V) (Xu et al., 2012). The chromatograms 208 
are presented in Figure S2. The sum of the arsenic speciation in the filtrate was considered 209 
the bioaccessible fraction (Sun et al., 2012). Bioaccessibility was calculated using the 210 









=  212 
where (Arsenic)filtrate is the total arsenic concentration (mg L
-1) in the 0.22 μm-filtered, fluid 213 
volume is the total volume of the gastric, small intestinal and colon fluid (L), (Arsenic)soil is 214 
the total arsenic concentration (mg kg-1) in the soil, and soil mass is the total mass (kg) of the 215 




2.7 Statistical analysis 217 
Statistical analysis was performed using SPSS Software 16.0. All statistical tests were 218 
considered significant at p<0.05. Graphs were generated with SigmaPlot 12.5 and Origin 219 
8.0. 220 
3. Results and Discussions 221 
3.1 Arsenic bioaccessibility and fractionation 222 
The arsenic bioaccessibility of soils was highly variable, ranging between 11.5-18.3%, 223 
14.7-32.5% and 19.7-36.9% in the gastric, small intestinal and colon phases, respectively 224 
(Figure 1). Arsenic bioaccessibility was < 40% in the digestive fluids, which confirmed that 225 
the arsenic could not be dissolved completely from the soil matrix. Previous studies 226 
demonstrated that chemical-form-oriented procedures could sufficiently define the mobile 227 
arsenic fraction in soils (Smith et al., 2008; Wan et al., 2017). To better understand the 228 
effects of the arsenic fraction on its bioaccessibility, two sequential extraction procedures 229 
(SEPs), including Tessier and Wenzel SEPs, were compared for arsenic fractionation in soils 230 
(Figure 2). The residual fractions extracted by the Tessier SEP (F5, accounting for 231 
51.9%~74.2% of total arsenic) and Wenzel SEP (RS5, accounting for 35.7%~51.7% of total 232 
arsenic) were dominant in soils, which implied that the residual fraction of arsenic in soils 233 
could be one of the reasons for the low arsenic bioaccessibility. The residual fraction is 234 
mainly composed of oxyanions, which are tightly bound to the mineral components of the 235 
soil, such as conichalcite [CaCu(AsO4)OH], arsenopyrite (FeAsS) and realgar (As4S4). All of 236 
these arsenic-containing ores in soils are indeed known to be less soluble than other forms of 237 
arsenic (Harvey et al., 2006; Meunier et al., 2010; Kim et al., 2014), resulting in a low level 238 




During the gastric digestive process, the bioaccessibility of arsenic in soil from the 240 
mining land (soil 1 and soil 2), chemical plants (soil 3 and soil 4) and battery plants (soil 5 241 
and soil 6) were 14.6%-14.8%, 16.0%-18.3%, and 11.5%-13.6%, respectively. The chemical 242 
plant soils showed a higher arsenic bioaccessibility than that of the mining and battery plant 243 
soils. The arsenic bioaccessibility was generally dependent on the type of soil. The battery 244 
plant soils exhibited significantly (p<0.05) higher arsenic bioaccessibility values 245 
(15.3%-32.5%) in the small intestinal phase than in the gastric phase. In contrast, the arsenic 246 
bioaccessibility in the mining and chemical plant soils remained constant during the 247 
digestive process from the gastric phase to the small intestinal phases. The bioaccessibility of 248 
arsenic was associated with arsenic fractionation (Kim et al., 2014; Palumbo-Roe et al., 249 
2015). A significant correlation was observed between arsenic bioaccessibility in the gastric 250 
phase and NS1+SS2+AF3 (r2=0.74, p<0.05), which was consistent with previous studies 251 
(Smith et al., 2008; Li et al., 2015). Li et al. (2015) compared the sequential extractable 252 
arsenic fractions with bioaccessible arsenic based on four assays, and they indicated that the 253 
exchangeable and outer-sphere (NS1), inner-sphere (SS2) and part of the amorphous and 254 
poorly crystalline hydrous oxides of Fe and Al fractions (AF3) were considered to be 255 
bioaccessible. The well-crystallized hydrous oxides of Fe and Al fraction (CF4) was thought 256 
to be relatively immobile. However, the first four fractions (AF1+SS2+AF3+CF4) extracted 257 
by the Wenzel SEP showed a strong correlation (r2=0.76, p<0.05) with arsenic 258 
bioaccessibility in the small intestinal phase, which implied that the CF4 fraction may 259 
contribute to bioaccessible arsenic. Furthermore, soil physicochemical properties, including 260 
the particle size fraction, soil organic matter (SOM), dissolved organic carbon (DOC), soil 261 
pH, and total manganese (Mn) and total iron (Fe) concentrations, were selected to explore 262 




DOC (r2 = 0.92. p <0.01) and SOM (r2 = 0.74. p <0.01) were identified as the two major 264 
physicochemical parameters influencing arsenic bioaccessibility in the gastric phase. The F4 265 
fraction (bound to organic matter) extracted by the Tessier SEP also showed a strong 266 
correlation with arsenic bioaccessibility in the gastric phase (r2=0.87, p<0.01). Arsenic is 267 
usually present as oxyanions in acidic environments, and organic matter carrying a negative 268 
charge could increase arsenic mobility by forming aqueous complexes, competing for 269 
adsorption sites or through electrostatic interactions (Wang and Mulligan, 2009).  270 
In the colon phase, the bioaccessibility of arsenic ranged from 19.7% to 36.9%, which 271 
was 1.3 to 2.1 times higher than that in the small intestinal phase, respectively. A sterile 272 
colon suspension from the dynamic SHIME was utilized to explore the effects of the colon 273 
microbial community on arsenic bioaccessibility (Figure S2). The arsenic bioaccessibility in 274 
the active colon phase was higher than that in the sterile colon phase. Similar results 275 
indicated that human colon microorganisms could increase arsenic bioaccessibility 276 
(Oremland and Stolz, 2005; Laird et al., 2007; Yin et al., 2015). Under the anaerobic 277 
conditions of the colon phase, there was abundant gut microbiota responsible for the 278 
reduction of As(V) to As(III), which possesses a lower affinity for sorption to iron oxides. 279 
Additionally, human gut microbiota could catalyze the reduction of iron oxides bearing 280 
arsenic. Both of these reductions could be reasons for the increase in arsenic bioaccessibility 281 
by gut microbiota. 282 
3.2 Arsenic speciation in the digestive tract 283 
Only inorganic arsenic was detected in all the soils, and As(V), accounting for 284 
86.0%~99.0% of the total extractable arsenic, was the dominant species in soils (Figure S5). 285 
After incubation of the active colon microbes, organoarsenicals, including two pentavalent 286 




a methylated thioarsenical species [MMMTA(V)], were detected simultaneously, which 288 
accounted for 17.8-41.5% of the total soluble arsenic in the colon phase (Figure 3c). Arsenic 289 
speciation in the sterile colon phase was also analyzed to confirm the contribution of gut 290 
microbiota to arsenic metabolism. Only inorganic arsenic, including As(III) and As(V), was 291 
found, with As(V) being dominant (Figure 3d). The amount of As(V) accounted for 46.7% 292 
and 76.8% of the total arsenicals in the active and sterile colons, respectively, suggesting the 293 
significant reduction of As(V) by gut microbes. Previous studies demonstrated that As(III) 294 
showed a lower affinity for sorption to iron oxides than that of As(V) (Cao et al., 2003; Dixit 295 
and Hering, 2003), and the high proportion of As(III) in the active colon phase could 296 
increase bioaccessibility (Yin et al., 2015). These results suggested that the presence of colon 297 
microorganisms not only increased the bioaccessibility of arsenic but also had the potential 298 
to actively metabolize inorganic arsenic into methylated arsenical and thioarsenical species, 299 
as reported in previous studies (Laird et al., 2007; Van de Wiele et al., 2010; Yin et al., 300 
2015). The colon microbial suspensions were collected from the improved SHIME model for 301 
16S rDNA extraction and then high throughput sequencing. The results showed that the 302 
average abundances of the Enterobacteriaceae and Bacteroides genera were 38.0% and 303 
22.3% respectively (Figure S4). Previous studies have shown that some species in the 304 
Enterobacteriaceae and Bacteroides genera can methylate arsenic (Isokpehi et al., 2014; Li et 305 
al., 2016; Yu et al., 2016). Thus, it is reasonable to hypothesize that human colon microbes 306 
have a high level of arsenic methylation potential. Compared with the diverse arsenic 307 
speciation in the colon phase, only inorganic arsenic was detected in the stomach and small 308 
intestinal phases (Figure 3a, 3b), and the dominant form was As(V), which accounted for 309 




Overall, As(III) rather than As(V) was the substrate for arsenic methylation, thus, the 311 
high reduction of As(V) in the active colon phases suggests the possibility of subsequent 312 
arsenic methylation in our study. Although the detailed mechanism of arsenic methylation is 313 
still a highly controversial topic, arsenic methylation has been proven to be catalyzed by the 314 
enzyme As(III) S-adenosylmethionine (SAM) methyltransferase (named ArsM in microbes 315 
and AS3MT in mammals) (Ajees and Rosen, 2015; Cai et al., 2018). It is also clear that the 316 
products of the enzyme are all trivalent and that the pentavalent species are the result of 317 
non-enzymatic oxidation in the air (Yang and Rosen, 2016). Thus, we proposed that 318 
intracellular As(III) was methylated by ArsMs from gut microbes to MMA(III) and DMA(III) 319 
and then oxidized to MMA(V) and DMA(V) by oxygen in the air during sample preparation 320 
and measurement. At the same time, dissolved oxygen is naturally present in gut fluids, and 321 
the oxidation process could also occur in the colon phase. This is further supported by the 322 
fact that DMA(III) is more sensitive to oxygen than MMA(III), and only MMA(III) but no 323 
DMA(III) was detected in the samples. Furthermore, because most intracellular As(III) is 324 
bound to intracellular thiols or thiols in proteins to yield trivalent protein-bound arsenicals 325 
under the exposure of glutathione (GSH), thiolation could be a competitive reaction to form 326 
stable pentavalent protein-bound arsenicals under the exposure of H2S, which can be further 327 
hydrolyzed to MMMTA(V) and DMMTA(V) (Sergio et al., 2014). In this study, due to the 328 
abundant presence of sulfate-reducing bacteria that produce H2S in the human fecal and 329 
colon microbiota, a considerable amount of MMMTA(V) was detected in the samples. 330 
However, the reason why no DMMTA(V) was detected needs further study. 331 
3.3 Implication for the health risk assessment 332 
Incidental soil ingestion is a potentially main route for non-dietary exposure to arsenic. 333 




daily amount of bioaccessible arsenic can be calculated by the following equation: the daily 335 
amount of bioaccessible arsenic (μg d-1) = soil ingestion rate (g d-1) × arsenic concentration 336 
in soil (μg g-1) × arsenic bioaccessibility (%). The variability of arsenic bioaccessibility using 337 
different in vitro models results in the conservative approach of assuming the 338 
bioaccessibility of arsenic is 100%. Nevertheless, our results showed that only a low level of 339 
arsenic could be dissolved from the soil matrix, and Yin et al. (2016) demonstrated that 340 
arsenic bioaccessibility values in the gastric and small intestinal fluids of the UBM-SHIME 341 
combined model were closed to that of the arsenic relative bioavailability. In this case, the 342 
low levels of arsenic bioaccessibility in our study suggested that the health risk assessment 343 
based on the total concentration would be overestimated. 344 
Furthermore, arsenic toxicity is one of the primary parameters for assessing the health 345 
risks associated with arsenic exposure. The toxicity of arsenic is highly dependent on its 346 
speciation (Bissen and Frimmel, 2003). Previous studies demonstrated that the LD50 of 347 
MMA(III) was 12 times lower than that of As(III), which indicated that MMA(III) is a much 348 
more toxicant and potent enzyme inhibitor than As(III) (Drobná et al., 2005; Petrick et al., 349 
2001). This is also reflected by a larger cellular uptake and accumulation of MMA(III) 350 
compared to As(III) in human urothelial cells and rat hepatocytes (Drobná et al., 2005; 351 
Styblo et al., 2000). Furthermore, the finding of MMMTA(V) formation by the human colon 352 
microorganisms raises questions about its toxicological importance. Hinrichsen et al. (2015) 353 
demonstrated that the cellular retention of MMMTA(V) was lower than that of DMA(V), but 354 
the intestinal transport of MMMTA(V) was similar to that of As(V) in Caco-2 cell assays. 355 
Although the absorption kinetics of MMMTA(V) across the epithelium is not well 356 
characterized, there is evidence that some methylated thio-arsenicals elicit a more efficient 357 




2007). In this case, the formation of MMMTA(V) and MMA(III) in the colon phase will 359 
increase the uncertainty of the human health risk assessment. Our observations emphasized 360 
the need to investigate the behavior of MMA(III) and MMMTA(V) in the gut lumen. 361 
Considering that the formation of highly toxic MMA(III) and MMMTA(V) with unknown 362 
toxicokinetic properties by colon microorganisms, the arsenic metabolism by human colon 363 
microorganisms should be considered seriously while assessing human health risk after oral 364 
exposure to soil. 365 
Conclusions 366 
We presented detailed results on the bioaccessibility of arsenic ranging between 11.5% 367 
and 18.3% in the stomach, 14.7% and 32.5% in the small intestine and 19.7% and 36.9% in 368 
the colon, respectively. The low level of arsenic bioaccessibility values demonstrated that 369 
human health risks are overestimated by using the total concentration. However, the 370 
formation of highly toxic MMA(III) and MMMTA(V) with unknown toxicokinetic 371 
properties in the colon phase implied an increase in uncertainty of human health risk. The 372 
formation of various organic arsenic species demonstrated that human colon microorganisms 373 
had the potential to actively metabolize soil inorganic arsenic into methylated arsenicals and 374 
methylated thioarsenicals. Herein, the arsenic metabolism by human colon microorganisms 375 
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Figure captions 384 
Figure 1 The bioaccessibility of arsenic in the digestive tract. (n=3). The different letters 385 
indicate significant differences between the samples at p<0.05 using a one-way ANOVA 386 
test. 387 
 388 
Figure 2 The distribution of arsenic fractionations by Wenzel SEP (a) and Tessier SEP (b). 389 
Non-specifically sorbed fraction (NS1), the specially-sorbed fraction (SS2), the amorphous 390 
and poorly-crystalline hydrous oxides of Fe and Al fraction (AF3), well-crystallized hydrous 391 
oxides of Fe and Al (CF4) and the residual phases (RS5). Exchangeable fraction (F1), bound 392 
to carbonates fraction (F2), bound to iron and manganese fraction (F3), bound to organic 393 
matter fraction (F4), the residual fraction (F5). 394 
 395 
Figure 3. Contents of chromatographically detected arsenic speciation [As(III), As(V), 396 
MMA(V), DMA(V), MMA(III) and MMMTA(V)] in gastric (a), small intestinal (b), active 397 
colon (c) and sterile colon (d) phases. Values are represented as averages ± standard 398 
deviation (n=3). Note that arsenic contents were presented as a bioaccessible fraction in 399 























Table 1 Physicochemical properties of the soils (values are represented as averages ± standard deviation, n=3) 411 
sample site type pH SOM (%) DOC (mg kg-1) 
particle size (%) 
As (mg kg-1) Fe (g kg-1) Al (g kg-1) Mn (g kg-1)  
clay silt 
soil 1 Chenzhou, Hunan mining land 7.33±0.08 1.83±0.02 133.52±23.15 1.69±0.04 36.92±1.94 777.25±20.51 22.48±1.28 28.33±2.84 2.85±0.17 
soil 2 Longyan, Fujian mining land 5.25±0.02 3.34±0.09 74.97±5.26 0.71±0.03 30.73±1.73 36.92±1.13 12.41±0.17 20.65±1.23 3.22±0.10 
soil 3 Suzhou, Jiangsu chemical land 6.76±0.06 16.79±0.13 372.23±45.99 6.32±0.23 34.22±0.93 33.09±0.72 17.17±0.65 28.05±1.09 0.28±0.01 
soil 4 Suzhou, Jiangsu chemical land 5.13±0.06 3.32±0.17 335.75±53.59 9.03±0.10 52.32±2.00 14.64±0.95 14.97±0.70 21.69±1.24 0.23±0.01 
soil 5 Chongqing battery plant 7.60±0.06 2.10±0.08 10.24±4.03 7.43±0.17 28.06±0.55 20.06±1.57 22.19±1.02 23.06±1.68 0.40±0.02 
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